Correlation between PD-L1 Expression of Non-Small Cell Lung Cancer and Data from IVIM-DWI Acquired during Magnetic Resonance of the Thorax: Preliminary Results.
intravoxel incoherent motion (IVIM)
non-small cell lung cancer (NSCLC)
programmed death-ligand 1 (PD-L1)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Nov 2022
16 Nov 2022
Historique:
received:
14
10
2022
revised:
12
11
2022
accepted:
14
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
27
11
2022
Statut:
epublish
Résumé
This study aims to investigate the correlation between intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) parameters in magnetic resonance imaging (MRI) and programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC). Twenty-one patients diagnosed with stage III NSCLC from April 2021 to April 2022 were included. The tumors were distinguished into two groups: no PD-L1 expression (<1%), and positive PD-L1 expression (≥1%). Conventional MRI and IVIM-DWI sequences were acquired with a 1.5-T system. Both fixed-size ROIs and freehand segmentations of the tumors were evaluated, and the data were analyzed through a software using four different algorithms. The diffusion (D), pseudodiffusion (D*), and perfusion fraction (pf) were obtained. The correlation between IVIM parameters and PD-L1 expression was studied with Pearson correlation coefficient. The Wilcoxon−Mann−Whitney test was used to study IVIM parameter distributions in the two groups. Twelve patients (57%) had PD-L1 ≥1%, and 9 (43%) <1%. There was a statistically significant correlation between D* values and PD-L1 expression in images analyzed with algorithm 0, for fixed-size ROIs (189.2 ± 65.709 µm²/s × 104 in no PD-L1 expression vs. 122.0 ± 31.306 µm²/s × 104 in positive PD-L1 expression, p = 0.008). The values obtained with algorithms 1, 2, and 3 were not significantly different between the groups. The IVIM-DWI MRI parameter D* can reflect PD-L1 expression in NSCLC.
Identifiants
pubmed: 36428726
pii: cancers14225634
doi: 10.3390/cancers14225634
pmc: PMC9688282
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Imaging Sci. 2011;1:27
pubmed: 21966624
Cancer Cytopathol. 2017 Dec;125(12):896-907
pubmed: 29024471
J Clin Oncol. 2022 Apr 20;40(12):1301-1311
pubmed: 35108059
Cancers (Basel). 2020 Dec 11;12(12):
pubmed: 33322522
Eur J Radiol. 2015 Mar;84(3):509-515
pubmed: 25554007
Thorac Cancer. 2020 Feb;11(2):362-368
pubmed: 31808285
JCI Insight. 2016 Sep 8;1(14):e89014
pubmed: 27699239
Diagn Interv Radiol. 2021 Mar;27(2):214-218
pubmed: 33455898
J Clin Oncol. 2022 Oct 28;:JCO2102885
pubmed: 36306479
BMC Cancer. 2020 Aug 24;20(1):799
pubmed: 32831052
J Thorac Dis. 2018 Nov;10(Suppl 33):S4031-S4033
pubmed: 30631547
J Immunother Cancer. 2022 Jun;10(6):
pubmed: 35649657
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
J Clin Oncol. 2017 Dec 10;35(35):3924-3933
pubmed: 29023213
Cancer Imaging. 2021 Jan 13;21(1):11
pubmed: 33441183
Radiology. 1986 Nov;161(2):401-7
pubmed: 3763909
IEEE Trans Med Imaging. 2018 Jan;37(1):35-46
pubmed: 28463188
Acta Radiol. 2019 Feb;60(2):168-176
pubmed: 29792040
Cancers (Basel). 2020 Oct 15;12(10):
pubmed: 33076303
Radiol Oncol. 2021 Jan 20;55(2):150-157
pubmed: 33764703
Magn Reson Med Sci. 2021 Jun 1;20(2):125-138
pubmed: 32536681
Magn Reson Imaging. 2019 May;58:24-31
pubmed: 30630071
J Thorac Imaging. 2013 May;28(3):138-50
pubmed: 23549390
Cancer Imaging. 2020 Jan 22;20(1):9
pubmed: 31969196
J Thorac Dis. 2019 Dec;11(12):4982-4991
pubmed: 32030214
Invest Radiol. 2016 Feb;51(2):90-9
pubmed: 26405835
Eur Radiol. 2021 Mar;31(3):1347-1358
pubmed: 32876833
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Front Oncol. 2021 Aug 23;11:703143
pubmed: 34497760
Eur Radiol. 2016 Aug;26(8):2547-58
pubmed: 26615557
Front Oncol. 2022 Mar 11;12:809430
pubmed: 35359367
J Thorac Oncol. 2022 Sep;17(9):e80-e83
pubmed: 36031295